Semaglutide 1.0 mg: First Therapeutic Dose (Weeks 9-12 or Long-Term Maintenance)
1.0 mg is where most patients first feel the full weight of GLP-1 appetite suppression. It's also the standard Ozempic maintenance dose and a clinically valid long-term setpoint for many Wegovy patients.
Semaglutide 1.0 mg occupies an important pivot point in the titration. It's the standard FDA-approved Ozempic maintenance dose for type 2 diabetes; it's the third weekly step in the Wegovy chronic weight management titration; and it's the lowest dose at which most patients feel the appetite-suppression effect strongly enough to drive consistent caloric deficit. Many patients reach 1.0 mg and never need to escalate further.
The therapeutic threshold
At 1.0 mg weekly, semaglutide produces near-maximal GLP-1 receptor occupancy. Gastric emptying slows by 60-80%; appetite signaling is meaningfully suppressed in most patients; insulin response to meals is significantly augmented. The STEP 1 NEJM 2021 trial shows weight loss rate accelerating steeply between 0.5 mg and 1.0 mg dosing periods.
Standard schedule: 0.25 mg (wks 1-4) → 0.5 mg (wks 5-8) → 1.0 mg (wks 9-12) → 1.7 mg (wks 13-16) → 2.4 mg (wks 17+). Trimi clinicians may extend the 1.0 mg block if patients are losing well and don't need additional escalation.
Maintenance at 1.0 mg vs escalating to 2.4 mg
Wegovy's FDA-approved chronic-weight-management dose is 2.4 mg. The 15-17% mean weight loss in STEP 1 was measured at the 2.4 mg dose. But many real-world patients maintain at 1.0 mg long-term — clinically reasonable for those who respond well, prefer fewer side effects, or want a slower weight-loss pace to minimize facial volume loss ("Ozempic face"). The trade-off: lower total weight loss potential vs better tolerance and cosmetic outcomes.
When to hold at 1.0 mg
- • Strong appetite suppression already — don't need more
- • Losing 0.5-1% body weight per week steadily — at target rate
- • Concerned about facial volume loss from faster pace
- • Significant side effects at higher doses — 1.0 mg is the tolerable plateau
When to escalate to 1.7 / 2.4 mg
- • Plateau at 1.0 mg with weight-loss stalling
- • Goal weight not yet reached and 1.0 mg appetite effect feels insufficient
- • Tolerating side effects well — escalation likely manageable
Start semaglutide with Trimi
$99/month annual plan, flat across all doses. Same active ingredient as Wegovy and Ozempic.
Start your visitFAQs
Is 1.0 mg semaglutide enough for weight loss?
For many patients, yes. 1.0 mg is the standard maintenance dose for Ozempic (type 2 diabetes) and is therapeutically active for weight loss — STEP trials show meaningful weight loss begins at this dose level, even though Wegovy's FDA-approved target is 2.4 mg. Highly responsive patients sometimes stay at 1.0 mg long-term rather than escalating to 1.7 or 2.4 mg, trading some additional weight loss for fewer side effects.
When do I escalate to 1.0 mg semaglutide?
Week 9, per the standard titration. After 4 weeks at 0.25 mg starter (weeks 1-4) and 4 weeks at 0.5 mg (weeks 5-8), most patients move to 1.0 mg in weeks 9-12. This is the dose where appetite suppression typically feels strongest and weight-loss rate accelerates.
How much weight loss should I expect at 1.0 mg?
Patients commonly lose 4-8 lbs during the 4 weeks at 1.0 mg (weeks 9-12), depending on baseline body weight and individual response. By the end of the 1.0 mg block, total weight loss from start is typically 5-12% of starting body weight.
Can I stay on 1.0 mg as maintenance?
Yes — clinically valid choice. Patients who respond well to 1.0 mg and don't want to push for maximum effect can maintain at this dose indefinitely. The trade-off vs 2.4 mg maintenance: less total weight loss potential (10-12% vs 15-17% mean per STEP 1), but fewer side effects and a lower risk of facial volume loss from rapid loss.
Do side effects increase at 1.0 mg vs 0.5 mg?
Modestly. The 1.0 mg step typically reintroduces nausea or constipation for 5-10 days post-increase, then settles. Patients who tolerated 0.5 mg well usually tolerate 1.0 mg with similar transient symptoms.
Is 1.0 mg semaglutide same as 1.0 mg Ozempic?
Yes — semaglutide is the active ingredient in both Ozempic and Wegovy, and 1.0 mg is 1.0 mg regardless of brand. Ozempic 1.0 mg is FDA-approved for type 2 diabetes; Wegovy uses higher doses (1.7, 2.4 mg) for chronic weight management. Compounded semaglutide at 1.0 mg is the same molecule at the same dose.
Related reading
Disclaimer: Informational, not medical advice. Compounded semaglutide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. Always consult a licensed clinician about dose titration. **The FDA does not review or approve any compounded medications for safety or effectiveness.